This study systematically reveals the multi-target effects of Aβ antibodies in neurons, glial cells, and the vascular system, providing critical theoretical support for optimizing immunotherapeutic strategies for Alzheimer's disease. It offers direct guidance for designing next-generation antibodies with enhanced brain distribution and cellular penetration capabilities.
Literature Overview
The article titled 'Passive amyloid-β immunotherapy in Alzheimer’s disease: a multicellular clearance system beyond plaque removal,' published in the journal Molecular Neurodegeneration, systematically explores the mechanisms of passive Aβ immunotherapy in Alzheimer’s disease (AD). It proposes that therapeutic efficacy stems not only from plaque clearance but also from a multicellular cooperative clearance network involving neurons, glial cells, and the vascular system. By integrating multi-level evidence from basic pathology to clinical translation, this study redefines the mode of action of Aβ antibodies.Background Knowledge
The core pathological features of Alzheimer’s disease (AD) are Aβ plaque deposition and tau protein tangles, with Aβ accumulation considered a key initiating driver of the disease. Although passive immunotherapies targeting Aβ have achieved clinical breakthroughs—such as the approval of aducanumab, lecanemab, and donanemab—their clinical benefits remain limited and are often accompanied by amyloid-related imaging abnormalities (ARIA), indicating significant bottlenecks in current strategies. Existing therapies primarily rely on clearing extracellular plaques, yet they overlook the critical role of intraneuronal Aβ (iAβ) in early neuronal dysfunction and fail to fully account for the dynamic interactions of antibodies with microglia, astrocytes, perivascular macrophages (PVMs), and meningeal lymphatic vessels (mLVs). Furthermore, the blood-brain barrier (BBB) restricts broad antibody distribution, resulting in incomplete clearance of plaques in deep brain regions. Therefore, enhancing brain delivery of antibodies, promoting synergistic clearance across multiple cell types, and reducing ARIA risk have become central challenges in current Aβ immunotherapy. Against this backdrop, the study introduces a new paradigm—'multicellular clearance network'—offering a systematic perspective to overcome existing limitations.
Research Methods and Experiments
The authors conducted a comprehensive analysis of extensive preclinical and clinical data, encompassing AD transgenic mouse models (e.g., 3xTg-AD, 5xFAD, APP/PS1), human brain tissue samples, and clinical trial results from approved or investigational Aβ antibodies (e.g., aducanumab, lecanemab, donanemab, gantenerumab). Using techniques such as immunohistochemistry, mass spectrometry imaging, PET scanning, and single-cell RNA sequencing, they systematically tracked the distribution of Aβ antibodies in the brain, their interactions with different cell types, and their impact on Aβ dynamics. Particular attention was paid to the localization and function of antibodies within neurons, microglia, astrocytes, PVMs, and mLVs. The study also compared different antibodies in terms of epitope specificity (e.g., N-terminal, mid-domain, C-terminal), IgG subtypes (IgG1 vs. IgG4), and their effects on FcγR-dependent clearance and inflammatory responses.Key Conclusions and Perspectives
Research Significance and Prospects
This study fundamentally expands our understanding of the mechanisms of Aβ immunotherapy, emphasizing that therapeutic effects result from a coordinated multicellular network rather than the simple sum of single-cell actions or plaque removal. This perspective opens new avenues for drug development: designing multifunctional antibodies with efficient brain penetration, neuron targeting, moderate Fc activation, and enhanced lymphatic drainage. It also suggests that future clinical trials should incorporate multidimensional biomarkers—including iAβ, neuroinflammation, and cerebrovascular function—to more comprehensively assess treatment responses.
In clinical monitoring, greater attention should be paid to the mechanisms underlying ARIA, particularly its association with APOEε4 allele, excessive microglial activation, and PVM functional status, to enable personalized risk prediction and management. Additionally, this framework supports the development of cell-type-specific delivery systems, such as targeting strategies mediated by TfR or LRP1, to enhance therapeutic precision.
For disease modeling, current AD animal models need to further integrate human immune system components (e.g., HSC-humanized mice) to more accurately simulate antibody interactions with human microglia and PVMs. Furthermore, composite phenotypic analysis systems incorporating iAβ, tau, neuroinflammation, and vascular function should be established to comprehensively evaluate new therapeutics.
Conclusion
This study redefines passive Aβ immunotherapy not merely as a 'plaque-clearing agent' but as a central regulator of a 'multicellular coordinated clearance system,' deeply revealing its complex interactions among neurons, glial cells, and the vascular system. This new paradigm not only explains the limited efficacy and frequent ARIA observed with current therapies but also provides a systematic blueprint for next-generation antibody design: achieving efficient, safe, and widespread Aβ clearance through optimized epitope selection, IgG subtypes, Fc functions, and brain delivery strategies. From bench to bedside, the study emphasizes moving beyond plaque quantification via PET imaging toward multidimensional biomarker monitoring to precisely assess treatment responses. For AD care systems, this marks a strategic shift from 'pathology clearance' to 'restoration of network homeostasis,' laying a theoretical foundation for truly disease-modifying therapies. Future research should focus on enhancing clearance efficiency while avoiding excessive immune activation, ultimately achieving safe and effective long-term interventions.
